Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$8.03 +2.7%	$7.19	$2.05 ▼ $8.72	$716.01M	-0.46	1.10 million shs	1.20 million shs
CCCC C4 Therapeutics	$2.60 -5.8%	$1.97	$1.09 ▼ $7.22	$185.05M	2.97	1.45 million shs	1.31 million shs
PHAT Phathom Pharmaceuticals	$10.63 +2.4%	$9.35	$2.21 ▼ $19.71	$754.14M	0.45	1.77 million shs	914,768 shs
SANA Sana Biotechnology	$3.47 +0.3%	$3.59	$1.26 ▼ $7.30	$825.19M	1.9	5.96 million shs	4.89 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-2.13%	-4.63%	-6.24%	+44.01%	+255.45%
CCCC C4 Therapeutics	-3.50%	+23.21%	+18.97%	+102.94%	-56.05%
PHAT Phathom Pharmaceuticals	+2.77%	0.00%	+30.57%	+166.15%	-19.47%
SANA Sana Biotechnology	+1.76%	+11.25%	-25.27%	+76.53%	-31.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	3.3965 of 5 stars	4.5	2.0	2.1	2.5	0.6
CCCC C4 Therapeutics	1.4352 of 5 stars	3.2	2.0	1.0	1.7	0.0
PHAT Phathom Pharmaceuticals	2.9729 of 5 stars	3.5	1.0	1.9	5.0	0.6
SANA Sana Biotechnology	3.0806 of 5 stars	3.5	3.0	2.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$11.75	46.33% Upside
CCCC C4 Therapeutics	2.33	Hold	$8.00	207.69% Upside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	64.63% Upside
SANA Sana Biotechnology	3.00	Buy	$8.00	130.55% Upside

Current Analyst Ratings Breakdown

Latest CCCC, PHAT, AMLX, and SANA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	AMLX Amylyx Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00
7/3/2025	SANA Sana Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
6/24/2025	AMLX Amylyx Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$17.00
6/24/2025	SANA Sana Biotechnology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00
6/17/2025	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/9/2025	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $17.00
6/9/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
5/30/2025	AMLX Amylyx Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	-$249K	-2,875.55	N/A	N/A	$1.88 per share	4.27
CCCC C4 Therapeutics	$34.24M	5.40	N/A	N/A	$2.45 per share	1.06
PHAT Phathom Pharmaceuticals	$114.04M	6.61	N/A	N/A	($5.72) per share	-1.86
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.52 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$301.74M	-$2.50	N/A	N/A	N/A	N/A	-82.48%	-70.15%	11/6/2025 (Estimated)
CCCC C4 Therapeutics	-$105.32M	-$1.58	N/A	N/A	N/A	-325.88%	-53.91%	-33.26%	10/30/2025 (Estimated)
PHAT Phathom Pharmaceuticals	-$334.33M	-$4.73	N/A	N/A	N/A	-289.51%	N/A	-90.40%	11/6/2025 (Estimated)
SANA Sana Biotechnology	-$266.76M	-$1.06	N/A	N/A	N/A	N/A	-91.96%	-43.07%	N/A

Latest CCCC, PHAT, AMLX, and SANA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	SANA Sana Biotechnology	-$0.20	-$0.16	+$0.04	-$0.39	N/A	N/A
8/7/2025	Q2 2025	AMLX Amylyx Pharmaceuticals	-$0.44	-$0.46	-$0.02	-$0.46	N/A	N/A
8/7/2025	Q2 2025	CCCC C4 Therapeutics	-$0.38	-$0.37	+$0.01	-$0.37	$5.24 million	$6.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	$1.02	12.65%	N/A	N/A	N/A
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	8.72	8.72
CCCC C4 Therapeutics	N/A	5.06	5.06
PHAT Phathom Pharmaceuticals	N/A	2.38	2.35
SANA Sana Biotechnology	N/A	2.47	2.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
CCCC C4 Therapeutics	78.81%
PHAT Phathom Pharmaceuticals	99.01%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	12.30%
CCCC C4 Therapeutics	8.73%
PHAT Phathom Pharmaceuticals	24.10%
SANA Sana Biotechnology	30.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.17 million	78.20 million	Optionable
CCCC C4 Therapeutics	150	71.17 million	64.96 million	Optionable
PHAT Phathom Pharmaceuticals	110	70.94 million	53.85 million	Optionable
SANA Sana Biotechnology	380	237.81 million	163.85 million	Optionable

CCCC, PHAT, AMLX, and SANA Headlines

Recent News About These Companies

Sana Biotechnology Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares

1 hour ago | tmcnet.com

Sana Biotechnology, Inc. Completes Sale of 3,358,208 Shares, Generating Approximately $86.3 Million in Gross Proceeds

1 hour ago | quiverquant.comQ

HC Wainwright Issues Optimistic Forecast for SANA Earnings

August 16, 2025 | marketbeat.com

Q3 EPS Forecast for Sana Biotechnology Raised by Analyst

August 16, 2025 | americanbankingnews.com

Sana Biotechnology drops Washington plant build-out, pivots to CDMOs instead

August 14, 2025 | fiercepharma.comF

Sana Biotechnology Reports Non-Cash Impairment Losses

August 14, 2025 | theglobeandmail.com

Brokerages Set Sana Biotechnology, Inc. (NASDAQ:SANA) Target Price at $8.00

August 14, 2025 | americanbankingnews.com

Sana Biotech Bails on Factory in Old AT&T Call Center

August 12, 2025 | finance.yahoo.com

Sana Biotechnology (NASDAQ:SANA) Posts Earnings Results, Beats Estimates By $0.04 EPS

August 12, 2025 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Buy" by Brokerages

August 12, 2025 | marketbeat.com

Sana: Q2 Earnings Snapshot

August 11, 2025 | sfgate.com

Sana suspends build-out of Bothell manufacturing facility

August 11, 2025 | bizjournals.com

Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates

August 11, 2025 | manilatimes.netM

Sana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still Intrigued

August 8, 2025 | seekingalpha.com

Sana Biotechnology (NASDAQ:SANA) Shares Gap Down - Here's What Happened

August 8, 2025 | marketbeat.com

Seattle biotech firm Sana Biotechnology raising $75 million through public offering

August 8, 2025 | bizjournals.com

Sana Biotechnology stock tumbles after pricing public offering

August 7, 2025 | investing.com

Sana Biotechnology 20.9M share Spot Secondary priced at $3.35

August 7, 2025 | msn.com

Sana Biotechnology Shares Tumble on Pricing of Public Offering

August 7, 2025 | marketwatch.com

Sana Biotechnology (SANA) Projected to Post Earnings on Thursday

August 7, 2025 | marketbeat.com

Sana Biotechnology Announces Pricing of Public Offering

August 6, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC, PHAT, AMLX, and SANA Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$8.03 +0.21 (+2.69%)

Closing price 04:00 PM Eastern

Extended Trading

$8.02 0.00 (-0.06%)

As of 05:20 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

C4 Therapeutics NASDAQ:CCCC

$2.60 -0.16 (-5.80%)

Closing price 04:00 PM Eastern

Extended Trading

$2.56 -0.04 (-1.54%)

As of 05:18 PM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Phathom Pharmaceuticals NASDAQ:PHAT

$10.63 +0.25 (+2.41%)

Closing price 04:00 PM Eastern

Extended Trading

$10.26 -0.37 (-3.48%)

As of 05:30 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Sana Biotechnology NASDAQ:SANA

$3.47 +0.01 (+0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$3.43 -0.04 (-1.15%)

As of 05:19 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time